Genetic variants in microsomal epoxide hydrolase influence carbamazepine dosing

Clinical Neuropharmacology

Volumn 32, Issue 4, 2009, Pages 205-212

  Makmor Bakry, Mohd ^a   Sills, Graeme J ^a,b   Hitiris, Nikolas ^a   Butler, Elaine ^a   Wilson, Elaine A ^a   Brodie, Martin J ^a  

^a Univ Div of Cardiovasc Med Sci   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Antiepileptic drugs; Carbamazepine; Cytochrome P450; Microsomal epoxide hydrolase; Pharmacogenetics

Indexed keywords

CARBAMAZEPINE; CYTOCHROME P450; DRUG METABOLIZING ENZYME; EPOXIDE HYDROLASE; GLUCURONOSYLTRANSFERASE; SODIUM CHANNEL;

ADOLESCENT; ADULT; AGED; ARTICLE; DEMOGRAPHY; EPILEPSY; FEMALE; GENE; GENE SEQUENCE; GENETIC CODE; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; GROUPS BY AGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; POLYMERASE CHAIN REACTION; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICONVULSANTS; CARBAMAZEPINE; EPILEPSY; EPOXIDE HYDROLASES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PHARMACOGENETICS; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; SEQUENCE ANALYSIS, DNA; YOUNG ADULT;

EID: 68949167778     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNF.0b013e318187972a     Document Type: Article

References (43)

1. Brodie MJ, Dichter MA. Established antiepileptic drugs. Seizure 1997;6:159-174.
2. Kwan P, Brodie MJ. Effectiveness of first antiepileptic drug. Epilepsia 2001;42:1255-1260.
3. Kwan P, Sills GJ, Brodie MJ. The mechanisms of action of commonly used antiepileptic drugs. Pharmacol Ther 2001;90:21-34.
4. Spina E. Carbamazepine: Chemistry, biotransformation, and pharmacokinetics. In: Levy RH, Mattson RH, Meldrum BS, Perucca E, eds. Antiepileptic Drugs. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2002:227-235.
5. Browne TR. Pharmacokinetics of antiepileptic drugs. Neurology 1998;51(suppl4):S2-S7.
6. Kim RB. Pharmacogenetics of CYP enzymes and drug transporters: Remarkable recent advances. Adv Drug Deliv Rev 2002;54:1241-1242.
7. Ramachandran V Shorvon SD. Clues to the genetic influences of drug responsiveness in epilepsy. Epilepsia 2003;44:33-37.
8. Meisler MH, Kearney JA. Sodium channel mutations in epilepsy and other neurological disorders. J Clin Invest 2005;1 15:2010-2017.
9. Smith CA, Harrison DJ. Association between polymorphism in gene for microsomal epoxide hydrolase and suspectibility to emphysema. Lancet 1997;350:630-633.
10. Bhasker CR, McKinnon W, Stone A, et al. Genetic polymorphism of UDP-glucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: Ethnic diversity of alleles and potential clinical significance. Pharmacogenetics 2000; 10:679-685.
11. van Schaik RHN, de Wildt SN, van Iperen NM, et al. CYP3A4-V polymorphism detection by PCR-restriction fragment length polymorphism analysis and its allelic frequency among 199 Dutch Caucasians. Clin Chem 2000;46:1834-1836.
12. Fukuen S, Fukuda T, Maune H, et al. Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5, 3 and 6, in a Japanese population. Pharmacogenetics 2002; 12:331-334.
13. Nakayama J, Yamamoto N, Hamano K, et al. Failure to find evidence for association between voltage-gated sodium channel gene SCN2A variants and febrile seizures in humans. Neurosci Lett 2002;329:249-251.
14. Xu J, Turner A, Little J, et al. Positive results in association studies are associated with departure from Hardy-Weinberg equilibrium: Hint for genotyping error? Hum Genet 2002;1 11:573-574.
15. Hosking L, Lumsden S, Lewis K, et al. Detection of genotyping errors by Hardy-Weinberg equilibrium testing. EurJ Hum Genet 2004; 12: 395-399.
16. Brodie MJ, Neil Johnson F. Carbamazepine in the treatment of seizure disorders: Efficacy, pharmacokinetics and adverse event profile. Rev Contemp Pharmacother 1997;8:87-122.
17. Pelkonen O, Myllynen P, Taavitsainen P, et al. Carbamazepine: A Fblind- assessment of CYP-associated metabolism and interactions in human liver-derived in vitro systems. Xenobiotica 2001;31:321-343.
18. Whitaker WR, Clare JJ, Powell AJ, et al. Distribution of voltage-gated sodium channel alpha-subunit and beta-subunit mRNAs in human hippocampal formation, cortex, and cerebellum. J Comp Neurol 2000;422:123-139.
19. Battino D, Croci D, Rossini A, et al. Serum carbamazepine concentrations in elderly patients: A case-matched pharmacokinetic evaluation based on therapeutic drug monitoring data. Epilepsia 2003;44:923-929.
20. Bourdet SV, Gidal BE, Alldredge BK. Pharmacologic management of epilepsy in the elderly. J Am Pharm Assoc (Wash) 2001;41:421-436.
21. Hassett C, Aicher L, Sidhu JS, et al. Human microsomal epoxide hydrolase: Genetic polymorphism and function expression in vitro of amino acid variants. Hum Mol Genet 1994;3:421-428.
22. Hassett C, Lin J, Carty CL, et al. Human hepatic microsomal epoxide hydrolase: Comparative analysis of polymorphic expression. Arch Biochem Biophys 1997;337:275-283.
23. Kitteringham NR, Davis C, Howard N, et al. Interindividual and interspecies variation in hepatic microsomal epoxide hydrolase activity: Studies with cis-stilbene oxide, carbamazepine 10,11-epoxide and naphthalene. J Pharmacol Exp Ther 1996;278:1018-1027.
24. Nakajima Y, Saito Y, Shiseki K, et al. Haplotype structures of EPHX1 and their effects on the metabolism of carbamazepine-10,11-epoxide in Japanese epileptic patients. Eur J Clin Pharmacol 2005;61:25-34.
25. Shimada T, Yamazaki H, Mimura M, et al. Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994;270:414-423.
26. Hesselink DA, van Schaik RHN, van der Heiden IP, et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 2003;74:245-254.
27. Goto M, Masuda S, Kiuchi T, et al. CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation. Pharmacogenetics 2004; 14:471-478.
28. Kivisto KT, Niemi M, Schaeffeler E, et al. Lipid-lowering response to statins in affected by CYP3A5 polymorphism. Pharmacogenetics 2004;14:523-525.
29. Wong M, Balleine RL, Collins M, et al. CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy. Clin Pharmacol Ther 2004;75:529-538.
30. Park JY, Kim KA, Park PW, et al. Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of alprazolam in healthy subjects. Clin Pharmacol Ther 2006;79:590-599.
31. Dally H, Edler L, Jager B, et al. The CYP3A4*1B allele increases risk for small cell lung cancer: Effect of gender and smoking dose. Pharmacogenetics 2003; 13:607-618.
32. Ohmori S, Nakasa H, Asanome K, et al. Differential catalytic properties in metabolism of endogenous and exogenous substrates among CYP3A enzymes expressed in COS-7 cells. Biochim Biophys Acta 1998;1380:297-304.
33. Huang W, Lin YS, McConn DJ II, et al. Evidence of significant contribution from CYP3A5 to hepatic drug metabolism. Drug Metab Dispos 2004;32:1434-1445.
34. Paris PL, Kupelian PA, Hall JM, et al. Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients. Cancer Epidemiol Biomarkers Prev 1999;8:901-905.
35. Seo T, NakadaN, UedaN, et al. Effect of CYP3A5*3 on carbamazepine pharmacokinetics in Japanese patients with epilepsy. Clin Pharmacol Ther 2006;79:509-510.
36. Cornelis MC, El-Sohemy A, Campos H. Genetic polymorphism of CYP1A2 increases the risk of myocardial infarction. J Med Genet 2004;41:758-762.
37. Moonen H, Engels L, Keinjans J, et al. The CYP1A2-164A->C polymorphism (CYP1A2*1F) is associated with the risk for colorectal adenomas in humans. Cancer Lett 2005;229:25-31.
38. Pavanello S, Pulliero A, Lupi S, et al. Influence of the genetic polymorphism in the 5¶-noncoding region of the CYP1A2 gene on CYP1A2 phenotype and urinary mutagenicity in smokers. Mutat Res 2005;587:59-66.
39. Sawyer MB, Innocenti F, Das S, et al. A pharmacogenetic study of uridine diphosphate-glucuronosyltransferase 2B7 in patients receiving morphine. Clin Pharmacol Ther 2003;73:566-574.
40. Thibaudeau J, Lepine J, Tojcic J, et al. Characterization of common UGT1A8, UGT1A9, and UGT2B7 variants with different capacities to inactivate mutagenic 4-hydroxylated metabolites of estradiol and estrone. Cancer Res 2006;66:125-133.
41. Coffman BL, King CD, Rios GR, et al. The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7-(268) and UGT2B7H(268). Drug Metab Dispos 1998;26:73-77.
42. Sills GJ, Mohanraj R, Butler E, et al. A single nucleotide polymorphism in the SCN2A gene is associated with uncontrolled epilepsy. Epilepsia 2004;45(suppl 7):226.
43. Tate SK, Depondt C, Sisodiya SM, et al. Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin. Proc Natl Acad Sci USA 2005;102:5507-5512.